GoodRx Holdings (GDRX) EBITDA (2019 - 2026)

GoodRx Holdings' EBITDA history runs 8 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 40.08% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $78.1 million (down 4.55% YoY), while the FY2025 annual figure was $91.7 million, up 30.34% from the prior year.
• EBITDA came in at $14.0 million for Q1 2026 at GoodRx Holdings, down from $22.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $26.8 million in Q2 2025 to a low of -$38.3 million in Q3 2023.
• A 5-year average of $8.4 million and a median of $14.6 million in 2025 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 552.38% in 2023 and fell as far as 1152.85% in 2023.
• GoodRx Holdings' EBITDA stood at $1.7 million in 2022, then tumbled by 1152.85% to -$18.3 million in 2023, then jumped by 199.41% to $18.2 million in 2024, then rose by 24.77% to $22.7 million in 2025, then sank by 38.24% to $14.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $14.0 million, $22.7 million, and $14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison